Page 418 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(46) Garattini S, Bertele’ V. Anything new in EU pharmacovigilance?
Eur. J. Clin. Pharmacol. 2011 Nov;67(11):1199-200.

(47) Garattini S, Bertele’ V (2010) Rosiglitazone and the need for a new
drug safety agency. Br Med J 341:c5506. doi:10.1136/bmj.c5506.

(48) http://www.nap.edu/catalog.php?record_id=11750#orgs.
(49) http://www.iom.edu/Reports/2006/The-Future-of-Drug-
Safety-Promoting-and-Protecting-the-Health-of-the-Public.aspx.
(50) Carpenter D. Reputation and Power: Organizational Image and
Pharmaceutical Regulation at the FDA. Princeton University Press; 2010.
(51) European Journal of Clinical Pharmacology 2011 10.1007/s00
228-011-1052-1 Anything new in EU pharmacovigilance? Silvio Garattini1
and Vittorio Bertele’1.
(52) Uncommon knowledge. Drug and Tuerapautics Bulletin. 2009 Nov
1; 47(11):121.
(53) Schwartz LM, Woloshin S, Welch HG. Using a Drug Facts Box to
Communicate Drug Benefits and Harms Two Randomized Trials. Ann In-
tern Med. 2009 Apr 21;150(8):516–27.
(54) Germany’s tough reimbursement rules cause drug companies to
consider alternative drug trial solutions—FT.com [Internet]. [cited 2012
Feb 15]. Available from: http://www.ft.com/cms/s/2/d458d470-4696-
11e1-89a8-00144feabdc0.html#axzz1mTzZ2jdb.
(55) http://www.isdbweb.org/publications/view/pharmacovigilance-
data (‘Broadening access to signal is a positive step, but access to VigiBase
is also needed’, ISDB, February 15th 2012).

‫ اﻟﺘﺠﺎ ِرب المﻌﻴﺒﺔ‬:‫اﻟﻔﺼﻞ اﻟﺮاﺑﻊ‬

(1) Anesthesiology News—Fraud Case Rocks Anesthesiology Commu-
nity [Internet]. [cited 2012 Feb 12]. Available from: www.anesthesiologyne

418